Long-term overall survival of patients diagnosed with pure tubular carcinoma of the breast might be affected by increased co-morbidities

2018 ◽  
Vol 117 (7) ◽  
pp. 1614-1614
Author(s):  
Kadri Altundag
Keyword(s):  
Overall Survival ◽  
Carcinoma Of The Breast ◽  
Tubular Carcinoma

In response to: Long-term overall survival of patients diagnosed with pure tubular carcinoma of the breast might be affected by increased co-morbidities

2018 ◽  
Vol 117 (7) ◽  
pp. 1615-1615
Author(s):  
Éric Poirier ◽  
Christine Desbiens ◽  
Brigitte Poirier ◽  
Dominique Boudreau ◽  
Simon Jacob ◽  
...  
Keyword(s):  
Overall Survival ◽  
Carcinoma Of The Breast ◽  
Tubular Carcinoma

Tubular carcinoma of the breast. A long term follow-up

1985 ◽  
Vol 9 (3) ◽  
pp. 271-280 ◽  
Author(s):  
P. H. B. CARSTENS ◽  
R. A. GFEENBERG ◽  
D. FRANCIS ◽  
H. LYON
Keyword(s):  
Carcinoma Of The Breast ◽  
Tubular Carcinoma ◽  
Long Term Follow Up

Characteristics and long-term survival of patients diagnosed with pure tubular carcinoma of the breast

2017 ◽  
Vol 117 (6) ◽  
pp. 1137-1143 ◽  
Author(s):  
Éric Poirier ◽  
Christine Desbiens ◽  
Brigitte Poirier ◽  
Dominique Boudreau ◽  
Simon Jacob ◽  
...  
Keyword(s):  
Carcinoma Of The Breast ◽  
Term Survival ◽  
Tubular Carcinoma ◽  
Long Term Survival

IPILIMUMAB IN PATIENTS WITH DISSEMINATED MELANOMA: THE N.N. PETROV NATIONAL MEDICAL RESEARCH CENTER OF ONCOLOGY EXPANDED ACCESS PROGRAM EXPERIENCE

2018 ◽  
Vol 64 (3) ◽  
pp. 388-393
Author(s):  
Yekaterina Anokhina ◽  
V. Rubinchik ◽  
Yekaterina Yaremenko ◽  
Gulfiya Teletaeva ◽  
Dilorom Latipova ◽  
...  
Keyword(s):  
Overall Survival ◽  
Adverse Events ◽  
Medical Research ◽  
Research Center ◽  
Expanded Access ◽  
Risk Of Death ◽  
National Medical ◽  
Expanded Access Program ◽  
Access Program

Ipilimumab (IPI) provides a ten-year overall survival in almost 20 % of selected patients participated in several phase II-III trials. However, the expanded access program (EAP) looks more like routine practice than like clinical trials& This is why the results of such application could be different. Here we present the long-term follow-up data of single center EAP. Ninety-six patients with disseminated melanoma progressing after at least one lines of drug therapy were included at the N.N. Petrov National Medical Research Center of Oncology. Sixty-seven (70 %) patients had stage IV M1c, 35 patients (36 %) had elevated LDH before initiating IPI therapy. All patients received IPI 3 mg / kg IV every 3 weeks for a maximum of 4 cycles. Totally, 320 cycles (mean - 3.3 per patient) were conducted. Grade 3-4 immuno-mediated adverse events (imAE) observed in 18 (19 %) patients. Three patients died of adverse events, possibly associated with ongoing therapy. The median time to progression was 3 (95 % CI, 2.4 to 3.5) mo., the median overall survival was 13 (95 % CI, 8.3 to17.6) mo. Previous immunotherapy with dendritic cell vaccines decreased the risk of death by 48 % (Log-rank p = 0.049). The wild type BRAF status increased three-year overall survival from 29 to 68 % (p = 0.042). Our data confirms long-term safety and efficacy of IPI in patients with pretreated disseminated melanoma in the close to real practice setting.

scholarly journals Combination of the G-8 Screening Tool and Hand-Grip Strength to Predict Long-Term Overall Survival in Non-Small Cell Lung Cancer Patients Undergoing Stereotactic Body Radiotherapy

Cancers ◽  
2021 ◽  
Vol 13 (13) ◽  
pp. 3363
Author(s):  
Kristian Kirkelund Bentsen ◽  
Olfred Hansen ◽  
Jesper Ryg ◽  
Ann-Kristine Weber Giger ◽  
Stefan Starup Jeppesen
Keyword(s):  
Overall Survival ◽  
Grip Strength ◽  
Cancer Patients ◽  
Stereotactic Body Radiotherapy ◽  
Statistical Significance ◽  
Multivariable Analysis ◽  
Hand Grip Strength ◽  
Physical Test ◽  
Hand Grip

The Geriatric 8 (G-8) is a known predictor of overall survival (OS) in older cancer patients, but is mainly based on nutritional aspects. This study aimed to assess if the G-8 combined with a hand-grip strength test (HGST) in patients with NSCLC treated with stereotactic body radiotherapy can predict long-term OS better than the G-8 alone. A total of 46 SBRT-treated patients with NSCLC of stage T1-T2N0M0 were included. Patients were divided into three groups: fit (normal G-8 and HGST), vulnerable (abnormal G-8 or HGST), or frail (abnormal G-8 and HGST). Statistically significant differences were found in 4-year OS between the fit, vulnerable, and frail groups (70% vs. 46% vs. 25%, p = 0.04), as well as between the normal and abnormal G-8 groups (69% vs. 39%, p = 0.02). In a multivariable analysis of OS, being vulnerable with a hazard ratio (HR) of 2.03 or frail with an HR of 3.80 indicated poorer OS, but this did not reach statistical significance. This study suggests that there might be a benefit of adding a physical test to the G-8 for more precisely predicting overall survival in SBRT-treated patients with localized NSCLC. However, this should be confirmed in a larger study population.

Sign in / Sign up

Export Citation Format

Share Document